Feng Yan, Song Li-Bing, Guo Bao-Hong, Liao Wen-Ting, Li Man-Zhi, Liu Wan-Li, Zeng Mu-Sheng, Zhang Ling
State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, PR China.
Ai Zheng. 2007 Feb;26(2):154-7.
BACKGROUND & OBJECTIVE: Bmi-1, a putative oncogene, is a member of the polycomb group genes family. It is widely expressed in many kinds of tumors. This study was to investigate the expression and significance of Bmi-1 in breast cancer.
The expression of Bmi-1 protein in 58 specimens of breast cancer was detected by immunohistochemistry. The correlation of Bmi-1 expression to clinicopathologic features of breast cancer was analyzed.
The intensive positive rate of Bmi-1 in breast cancer was 82.8%. The intensive expression of Bmi-1 was positively correlated to clinical stage and lymph node metastasis (P < 0.05), but not to tumor size, estrogen receptor (ER), progesterone receptor (PR), c-erbB-2 and vascular endothelial growth factor (VEGF) expression (P>0.05).
The intensive expression of Bmi-1 in breast cancer is related to tumor progression. Bmi-1 may serve as a new molecular marker of metastasis of breast cancer.
Bmi-1是一种假定的癌基因，属于多梳蛋白家族基因成员。它在多种肿瘤中广泛表达。本研究旨在探讨Bmi-1在乳腺癌中的表达及意义。
采用免疫组织化学法检测58例乳腺癌标本中Bmi-1蛋白的表达。分析Bmi-1表达与乳腺癌临床病理特征的相关性。
乳腺癌中Bmi-1的强阳性率为82.8%。Bmi-1的强表达与临床分期和淋巴结转移呈正相关（P<0.05），但与肿瘤大小、雌激素受体（ER）、孕激素受体（PR）、c-erbB-2和血管内皮生长因子（VEGF）表达无关（P>0.05）。
Bmi-1在乳腺癌中的强表达与肿瘤进展有关。Bmi-1可能作为乳腺癌转移的一种新的分子标志物。
